A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate

Osteopenia, Osteoporosis Clinical Trial

Official title:

A Double-Blinded Randomized Controlled CER Study of Changes in Bone Mineral Density, Blood Chemistries, Self-Reported Quality of Life and Compliance as a Function of Consuming Micronized Versus Non-micronized Calcium Carbonate

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01857154
• Other study ID #: 064
• Status: Recruiting
• Phase: N/A
• First received: May 8, 2013
• Last updated: November 21, 2013
• Start date: May 2013
• Est. completion date: October 2014

Study information

• Verified date: November 2013
• Source: Integrative Health Technologies, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether consuming calcium carbonate that has been micronized is more effective than the traditional form of calcium carbonate in maintaining or increasing bone mineral density in people who are currently taking bisphosphonates or other bone-health medications.

Description:

Addressing the need for a form of supplemental calcium that could facilitate increases in BMD without the adverse effects often reported with limestone-based forms of calcium, a patented technology was developed to increase calcium absorbability using both Zet Mill/Ball Mill bottom-up pulverizing technology and 4D top-down ebonite charging technology to create a novel form of calcium referred to as micronized calcium carbonate (MCC). In comparison to other technologies that use water and high heat, which results in a loss of core nutrients and decreased product efficacy, the calcium produced by this unique pulverizing technology is micron-sized (0.03um - 10um) and therefore believed to be more effective. While its tiny size was thought to increase its absorption, the belief was that the intense activation of zinc via the patented ebonite charging process that could maximize the bioavailability of this calcium.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: October 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Must currently be under the care of a physician and taking prescription medication for bone health

• Must ensure with medical provider that there are no medical conditions that would preclude participation

• Must be able to swallow capsules

• Must be age 21 or above

• Must agree to follow study requirements as set forth in Informed Consent

Exclusion Criteria:

• Men and women not currently taking prescription medication for bone health

• Conditions that inhibit gastrointestinal absorption of supplements

• Men and women less than 21 years of age

• Pregnant or breast feeding

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)

Related Conditions & MeSH terms

• Osteopenia, Osteoporosis

Intervention

Dietary Supplement:
• Micronized Calcium Carbonate
Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate. Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.
• Non-Micronized Calcium Carbonate
Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate. Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate.
• Vitamin D3
All subjects in the study cohort will be administered 800 IU Vitamin D3.

Locations

Country	Name	City	State
United States	Integrative Health Technologies	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Integrative Health Technologies, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in Bone Mineral Density as a measurement by Dual Energy X-ray Absorptiometry	Bone density scanning, also called dual-energy x-ray absorptiometry (DXA) or bone densitometry, is an enhanced form of x-ray technology that is used to measure bone mineral density. Imaging with x-rays involves exposing a part of the body to a small dose of ionizing radiation to produce pictures of the inside of the body.; Benefits; DXA bone densitometry is a simple, quick and noninvasive procedure.; No anesthesia is required.; The amount of radiation used is extremely small—less than one-tenth the dose of a standard chest x-ray, and less than a day's exposure to natural radiation.; DXA bone density testing is the most accurate method available for the diagnosis of osteoporosis and is also considered an accurate estimate	0 and 183 days	No
Secondary	Blood Chemistry Panel	43 chemistries including lipids, Complete Blood Count, metabolic panel, Thyroid Stimulating Hormone and Cardio C-reactive Protein	0 and 183 days	Yes
Secondary	Systolic and Diastolic blood pressure	Measures the amount of force (pressure) that blood exerts on the walls of blood vessels as it passes through them. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic pressure is a measure of blood pressure while the heart is relaxed, between heartbeats. Measurements will be taken after lying down for at least 5 minutes. Changes will be reported between baseline and day 183 of study.	0 and 183 days	Yes
Secondary	Resting heart rate	Measure of heart rate after lying down for at least 5 minutes. Changes will be reported between baseline and day 183 of study.	0 and 183 days	Yes
Secondary	Self-reported quality of life		0 and 183 days	Yes
Secondary	Number of participants with adverse effects	Participants will have opportunity to report on a weekly basis an adverse effects experienced	up to 183 days	Yes